Puneet Souda
Stock Analyst at Leerink Partners
(1.98)
# 3,085
Out of 5,127 analysts
219
Total ratings
47.75%
Success rate
-0.82%
Average return
Main Sectors:
Stocks Rated by Puneet Souda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Outperform | $115 → $155 | $105.03 | +47.58% | 7 | Dec 15, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Outperform | $545 → $580 | $539.80 | +7.45% | 20 | Oct 22, 2025 | |
| HOLX Hologic | Maintains: Market Perform | $70 → $78 | $75.15 | +3.79% | 8 | Oct 21, 2025 | |
| CYRX Cryoport | Upgrades: Outperform | $16 | $8.70 | +83.91% | 7 | Aug 6, 2025 | |
| MASS 908 Devices | Upgrades: Outperform | $12 | $6.77 | +77.25% | 7 | Aug 5, 2025 | |
| QTRX Quanterix | Downgrades: Market Perform | $12 → $8 | $6.12 | +30.72% | 12 | Apr 30, 2025 | |
| NEO NeoGenomics | Downgrades: Market Perform | $25 → $9 | $11.50 | -21.74% | 10 | Apr 30, 2025 | |
| MYGN Myriad Genetics | Downgrades: Market Perform | $30 → $21 | $5.08 | +313.39% | 7 | Dec 9, 2024 | |
| VCYT Veracyte | Maintains: Outperform | $35 → $40 | $37.03 | +8.02% | 14 | Oct 17, 2024 | |
| NTRA Natera | Maintains: Outperform | $140 → $150 | $211.65 | -29.13% | 7 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $325 → $375 | $327.02 | +14.67% | 15 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $35 | $32.37 | +8.12% | 11 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $170 → $145 | $129.00 | +12.40% | 19 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $300 | $219.75 | +36.52% | 1 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $249 → $250 | $119.32 | +109.52% | 19 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $110 | $64.80 | +69.75% | 6 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $75 | $103.35 | -27.43% | 16 | Jan 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $230 → $200 | $143.06 | +39.80% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $3.16 | +469.62% | 6 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $1.73 | +246.82% | 1 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $45 → $30 | $49.06 | -38.85% | 6 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $87 | $41.58 | +109.24% | 13 | May 5, 2022 |
Guardant Health
Dec 15, 2025
Maintains: Outperform
Price Target: $115 → $155
Current: $105.03
Upside: +47.58%
Thermo Fisher Scientific
Oct 22, 2025
Maintains: Outperform
Price Target: $545 → $580
Current: $539.80
Upside: +7.45%
Hologic
Oct 21, 2025
Maintains: Market Perform
Price Target: $70 → $78
Current: $75.15
Upside: +3.79%
Cryoport
Aug 6, 2025
Upgrades: Outperform
Price Target: $16
Current: $8.70
Upside: +83.91%
908 Devices
Aug 5, 2025
Upgrades: Outperform
Price Target: $12
Current: $6.77
Upside: +77.25%
Quanterix
Apr 30, 2025
Downgrades: Market Perform
Price Target: $12 → $8
Current: $6.12
Upside: +30.72%
NeoGenomics
Apr 30, 2025
Downgrades: Market Perform
Price Target: $25 → $9
Current: $11.50
Upside: -21.74%
Myriad Genetics
Dec 9, 2024
Downgrades: Market Perform
Price Target: $30 → $21
Current: $5.08
Upside: +313.39%
Veracyte
Oct 17, 2024
Maintains: Outperform
Price Target: $35 → $40
Current: $37.03
Upside: +8.02%
Natera
Oct 17, 2024
Maintains: Outperform
Price Target: $140 → $150
Current: $211.65
Upside: -29.13%
Aug 1, 2024
Upgrades: Outperform
Price Target: $325 → $375
Current: $327.02
Upside: +14.67%
Jun 5, 2023
Maintains: Outperform
Price Target: $50 → $35
Current: $32.37
Upside: +8.12%
May 24, 2023
Maintains: Outperform
Price Target: $170 → $145
Current: $129.00
Upside: +12.40%
May 1, 2023
Initiates: Outperform
Price Target: $300
Current: $219.75
Upside: +36.52%
Feb 8, 2023
Maintains: Outperform
Price Target: $249 → $250
Current: $119.32
Upside: +109.52%
Feb 3, 2023
Maintains: Outperform
Price Target: $125 → $110
Current: $64.80
Upside: +69.75%
Jan 12, 2023
Maintains: Outperform
Price Target: $70 → $75
Current: $103.35
Upside: -27.43%
Jan 6, 2023
Maintains: Outperform
Price Target: $230 → $200
Current: $143.06
Upside: +39.80%
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $3.16
Upside: +469.62%
Nov 29, 2022
Initiates: Outperform
Price Target: $6
Current: $1.73
Upside: +246.82%
Nov 21, 2022
Maintains: Market Perform
Price Target: $45 → $30
Current: $49.06
Upside: -38.85%
May 5, 2022
Maintains: Outperform
Price Target: $85 → $87
Current: $41.58
Upside: +109.24%